Patents Examined by Marcela M. Cordero Garcia
  • Patent number: 10457716
    Abstract: The instant disclosure provides a microscale method for providing correctly folded, and assembled biologically active proteins in an efficient and shorted time frame, compared to conventional protein production techniques. Proteins produced from inclusion bodies and other aggregated protein sources are provided. Microscale production of correctly folded and assembled class I MHC protein and complexes thereof are also provided for, as well as for high throughput production for use in epitope discovery protocols. Microscale production of complex proteins from protein aggregates and preparations containing protein aggregates is provided that requires less than 24 hours of processing time.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: October 29, 2019
    Assignee: University of Notre Dame du Lac
    Inventors: Brian M Baker, Lance Hellman
  • Patent number: 10450343
    Abstract: The present invention relates to a method of synthesizing a peptide product comprising at least one cyclic imide group. Further, the invention relates to a peptide product comprising at least one cyclic imide group, which is substantially free from degradation products. The peptide product may be used as a reference material for the quality control of pharmaceutical peptides, particularly for the quality control of a GLP-1 agonist like exendin peptides.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: October 22, 2019
    Inventor: Bernd Henkel
  • Patent number: 10449235
    Abstract: Some embodiments are directed to the use of creatine kinase or fragments thereof which induce analgesia, and also to the use of pharmaceutical compositions including the same, to relieve pain.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: October 22, 2019
    Inventors: Yannick Goumon, Jinane Mouheiche, Alexis Laux-Biehlmann, Pierrick Poisbeau, Nisrine Kamoun
  • Patent number: 10449259
    Abstract: The disclosure provides compositions comprising peptide-based nanofiber precursors and methods of using the same to inhibit cancerous cell growth and/or to deliver therapeutic or diagnostic agents to cells, e.g., cancerous cells. The compositions of the present technology include peptide-based nanofiber precursors as well as carrier complexes comprising a therapeutic or diagnostic agent, and a peptide-based nanofiber precursor. Also provided herein are methods for delivering a therapeutic or diagnostic agent to a cell comprising contacting the cell with a carrier complex including a therapeutic or diagnostic agent, and a peptide-based nanofiber precursor.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: October 22, 2019
    Inventors: Shek Hang Benedict Law, Ching-Hsuan Tung, Vanessa Bellat
  • Patent number: 10442835
    Abstract: The present invention relates to technical fields of organic chemistry and pharmaceutical chemistry, specifically to water-soluble rapamycin derivatives modified with glutathione. More specifically, the present invention discloses a compound of formula I and the preparation method thereof, wherein R1 and R2 are as defined in the description. The compound of formula I can be used in inducing immunosuppression and in the treatment of diseases such as transplant rejection and solid tumor, etc.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: October 15, 2019
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Haibo Wang, Hongfu Kuang, Wei Zhang, Zhengjiang Cai, Tianmin Zhu, Xiaohe Zheng, Zhongwei Wu, Zhiqing Yang
  • Patent number: 10435434
    Abstract: Disclosed herein are deuterated compounds, pharmaceutical compositions thereof, and methods for treating ETBR-related cancers. Also disclosed herein is a delivery system for the controlled, systemic release of at least one deuterated ETBR antagonist, optionally in conjunction with an additional anti-oncologic agent.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: October 8, 2019
    Inventor: Sumayah Jamal
  • Patent number: 10426850
    Abstract: The present invention provides both a caged collagen mimetic peptide (CCMP) having the formula: L-S-Zm-[Gly-X-Y]n-LGly-X-Y-[Gly-X-Y]n (SEQ ID NO: 19); wherein L is one or more detectable moieties; S is one or more spacer molecules; Zm is any amino acid where m is an integer of 1 to 10; X is proline or modified proline; Y is proline or modified proline; Gly is glycine; n is an integer from 1 to 20; and LGly is a glycine covalently linked to a cage moiety comprising a labile protecting group, as well as a collagen mimetic peptides lacking the labile protecting group (CMP). The inventions are useful for binding collagen and denatured collagen and/or gelatin both in vitro and in vivo, and are useful for targeting any organ or tissue where collagen is present, and can be used for research and diagnostic imaging (both in vivo and in vitro) and also for in vivo therapeutic applications.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: October 1, 2019
    Inventors: Michael S. Yu, Yang Li, Daniel Summerfield, Allen Yi-Lan Wang, Catherine A. Foss, Martin G. Pomper
  • Patent number: 10428114
    Abstract: Provided is a nRGD polypeptide formed by connecting alanine-alanine-asparagine (AAN) and a polypeptide containing arginine-glycine-aspartic acid (RGD), wherein the nRGD polypeptide can target tumor vessels, tumor cells and tumor-associated macrophages, and mediate the targeted delivery of tumors.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: October 1, 2019
    Inventors: Zhirong Zhang, Tao Gong, Yan Zhang, Xu Song, Tijia Chen, Yao Fu, Xun Sun, Xiaoqing Bai, Bei Zhang
  • Patent number: 10429300
    Abstract: The present invention provides assays utilizing SPR to detect protein-ligand interactions as well as compositions utilized is such assays.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: October 1, 2019
    Assignees: The Johns Hopkins University, Le Centre National de la Recherche Scientifique, Aix-Marseilles University
    Inventors: Frank Bosmans, Pierre E. Bougis, Marie-France Eauclaire
  • Patent number: 10426817
    Abstract: The present disclosure provides apolipoprotein (apo) mimetics useful for the treatment of age-related macular degeneration (AMD) and other eye disorders. The apo mimetics can be peptides/polypeptides that mimic, e.g., the lipid-clearing action of apolipoproteins such as apoA-I and apoE. The apo mimetics can exert other beneficial effects, such as reduction of inflammation, oxidative stress and neovascularization. The apo mimetics can be used to treat any stages (including the early, intermediate and advance stages) of AMD, and any phenotypes of AMD, including geographic atrophy (GA) (including non-central GA and central GA) and neovascularization (NV) (including types 1, 2 and 3 NV). The apo mimetics can be used alone or in conjunction with other therapeutic agents, such as a complement inhibitor and/or an anti-angiogenic agent, to treat AMD, including atrophic AMD and neovascular AMD, and other eye disorders.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: October 1, 2019
    Assignee: MacRegen, Inc.
    Inventors: Martin Rudolf, Keith Roizman
  • Patent number: 10421786
    Abstract: This disclosure relates to peptides useful for targeting inflamed or distressed tissue and uses related thereto. In certain embodiment, the peptides comprise SEQ ID NO: 1-14, or variants or derivatives thereof. In certain embodiments, peptides disclosed herein are conjugated to a label to detect, measure, or image cardiac tissue useful in the diagnosis of myocarditis. In certain embodiments, the peptides are conjugated to a particle coating for use in ultrasound imaging, MRI, or targeted therapy. In certain embodiments, peptides disclosed herein are conjugated to a drug or a particle containing a drug useful for targeted therapy.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: September 24, 2019
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Michael Davis, Mario Martinez
  • Patent number: 10420813
    Abstract: The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, Alzheimer's disease, allergic disease, transplant and cell graft rejection, HIV infection and other viral, bacterial, and parasitic infection, and AIDS. Methods are also provided for preparing a peptide having the property of being able to displace CLIP by feeding one or more peptide sequences into software that predicts MHC Class II binding regions in an antigen sequence and related products.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: September 24, 2019
    Assignee: The Regents of the University of Colorado, a Body Corporate
    Inventors: Martha Karen Newell-Rogers, Evan Newell
  • Patent number: 10420844
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: September 24, 2019
    Assignee: Mederis Diabetes LLC
    Inventor: John J. Nestor
  • Patent number: 10398781
    Abstract: Conjugates which comprise a drug and a ligand which includes a first saccharide; wherein the conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic or pharmacodynamic property of the conjugate is sensitive to serum concentration of a second saccharide. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: September 3, 2019
    Assignee: SMARTCELLS, INC.
    Inventors: Todd C. Zion, Thomas M. Lancaster
  • Patent number: 10400010
    Abstract: This invention relates, e.g., to an inhibitory peptide or CPP inhibitor which specifically binds to p53 having an aberrant conformation (e.g., is aggregated or misfolded) and inhibits p53 amyloidogenic aggregation or restores proper folding of the misfolded protein. Methods of using the inhibitory peptide or CPP inhibitor (e.g. to treat subjects having tumors that comprise aggregated p53) are described.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: September 3, 2019
    Inventors: David S. Eisenberg, Alice Soragni, Lin Jiang
  • Patent number: 10391151
    Abstract: In permeability lung edema, cardiogenic lung edema or neonatal respiratory distress, there is heterogeneous liquid distribution throughout the lungs. The excess alveolar liquid reduces gas exchange. Mechanical ventilation is used to improve gas exchange. In the presence of heterogeneous liquid distribution, there are surface tension-dependent stress concentrations in septa separating aerated from flooded alveoli. Mechanical ventilation, by inflating the lung above normal volumes, thus increasing surface tension above normal, exacerbates the stress concentrations and consequently injures, or exacerbates pre-existing injury of, the alveolar-capillary barrier. Any means of lowering surface tension should lessen ventilation injury of the lung. In the present invention, dilute exogenous surfactant solution or surfactant protein C solution interacts with albumin to lower surface tension, likely through effective promotion of surfactant lipid adsorption.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: August 27, 2019
    Assignee: The Trustees of the Stevens Institute of Technology
    Inventor: Carrie E. Perlman
  • Patent number: 10392428
    Abstract: The invention relates to a derivative of a GLP-1 analog of a general Formula I, which derivative comprises a side chain attached to a Lys residue at position 34, 35, 36, 37, 38, or 39 of the GLP-1 analog. The side chain comprises a Branched linker, a 1st and a 2nd Protractor and a Pre-linker. The Branched linker is connected to the Lys residue of the GLP-1 analog via the Pre-linker and to the 1st and the 2nd Protractor via a 1st and 2nd Post-linker, respectively. The Branched linker may, e.g., be a tri-radical of Lys. The 1st and the 2nd Protractor is C20 diacid. Various linker elements may be used in the Prelinker as well as the two Post-linkers. The invention also relates to novel GLP-analogs, novel side chain intermediates and their manufacture and use to prepare derivatives of biologically active peptides and proteins, as well as pharmaceutical compositions and medical uses of the analogs and derivatives.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: August 27, 2019
    Assignee: Novo Nordisk A/S
    Inventor: Jacob Kofoed
  • Patent number: 10383796
    Abstract: The present invention relates to the uses of the protein PRG4 and therapeutic modulation thereof. In particular, the present invention relates compositions and methods utilizing PRG4 and therapeutic modulation thereof, including, use as a surgical lubricant, use in a treatment for prevention or reduction of post-surgical adhesions, use in a treatment for oral ulcerations, use as an athletic lubricating patch, use as a dermal filler, use in a treatment for dry mouth, use in a drug delivery method or composition, and use in nursing lubrication.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: August 20, 2019
    Assignee: Lubris LLC
    Inventors: Edward R. Truitt, Nicole Barbara Justis Truitt
  • Patent number: 10376558
    Abstract: Methods and compositions for synchronizing the time of insemination in gilts are provided. More particularly, methods and compositions for synchronizing the time of insemination in gilts using a gonadotropin-releasing hormone and a hormone for synchronizing estrus are provided.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: August 13, 2019
    Assignee: United-AH II, LLC
    Inventors: Stephen Kent Webel, Mark E. Swanson, Robert R. Kraeling, Michael E. Johnston
  • Patent number: 10370425
    Abstract: The embodiments provide a modified calcitonin gene-related peptide antagonist including an N-terminal fragment of modified calcitonin gene-related peptide or related protein family member where at least two residues of the N-terminal fragment are cysteine (Cys) and at least one amino acid comprises a non-threonine substitution of a threonine (Thr) residue; a central core where the central core comprises an a-helix; and a C-terminal fragment of modified calcitonin gene-related peptide or related protein family member comprising a C-terminal amide and where at least one amino acid of the C-terminal fragment is phenylalanine (Phe), proline (Pro), tyrosine (Tyr) or hydroxyproline (Hyp) or pharmaceutically acceptable salt thereof, as well as compositions, including pharmaceutical compositions, comprising a subject peptide.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: August 6, 2019
    Inventor: Christopher Joseph Soares